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Abstract
Background: Imepitoin was tested as a combination treatment with phenobarbital in an open-label mono-centre
cohort study in dogs with drug-resistant epilepsy. Diagnosis of idiopathic epilepsy was based on clinical findings,
magnetic resonance imaging and cerebrospinal fluid analysis. Three cohorts were treated. In cohort A, dogs not
responding to phenobarbital with or without established add-on treatment of potassium bromide or levetiracetam
were treated add-on with imepitoin, starting at 10 mg/kg BID, with titration allowed to 30 mg/kg BID. In cohort B,
the only difference to cohort A was that the starting dose of imepitoin was reduced to 5 mg/kg BID. In cohort C,
animals not responding to imepitoin at >20 mg/kg BID were treated with phenobarbital add-on starting at
0.5 mg/kg BID.
Results: The add-on treatment resulted in a reduction in monthly seizure frequency (MSF) in all three cohorts.
A reduction of ≥50% was obtained in 36-42% of all animals, without significant difference between cohorts.
The lower starting dose of 5 mg/kg BID imepitoin was better tolerated, and an up-titration to on average of
15 mg/kg BID was sufficient in cohort A and B. In cohort C, a mean add-on dose of 1.5 mg/kg BID phenobarbital was
sufficient to achieve a clinically meaningful effect. Six dogs developed a clinically meaningful increase in MSF of≥ 50%,
mostly in cohort A. Neither imepitoin nor phenobarbital add-on treatment was capable of suppressing cluster seizure
activity, making cluster seizure activity an important predictor for drug-resistance.
Conclusion: A combination treatment of imepitoin and phenobarbital is a useful treatment option for a subpopulation
of dogs with drug-resistant epilepsy, a low starting dose with 5 mg/kg BID is recommended.
Keywords: Idiopathic epilepsy, Combination treatment, Potassium bromide, Levetiracetam, Anticonvulsant, Tonic-clonic
seizures
Background
Idiopathic epilepsy is defined as chronic spontaneous
seizure activity and can be sub-classified into three sub-
groups: genetic epilepsy, suspected genetic epilepsy, and
epilepsy of unknown cause, in which the nature of the
underlying cause is unknown and no indication of struc-
tural epilepsy occurs [1]. Idiopathic epilepsy is diagnosed,
if the dog experienced the first seizure activity at an age of
6 months up to 6 years, if reasons for structural epilepsy
or reactive seizures (due to extracranial causes) are ex-
cluded and if the dog does not show neurological abnor-
malities in the interictal period. Magnetic resonance
imaging (MRI) and cerebrospinal fluid (CSF) analysis
showing a lack of structural pathology supports the diag-
nosis [1, 2]. Familial predisposition or predisposition in
some dog breeds is described [3]. In these breeds, such as
Australian Shepherds and Border Collies, a severe course
of the disease is seen [1, 4, 5]. The treatment of epilepsy is
hampered by the fact that 20-40% of dogs with idiopathic
epilepsy may be treatment-resistant to one or several anti-
epileptic medications [3]. In these cases, an additional
medication is recommended (add-on treatment).
Imepitoin is a partial agonist at the benzodiazepine
recognition site of the γ-amino butyric acid (GABAA)
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receptor that was developed as an antiepileptic (antisei-
zure) drug (AED) for canine idiopathic epilepsy [6–9].
Since its introduction in 2013, imepitoin has become
one of the two AEDs with the highest level of evidence
for efficacy for the treatment of generalized tonic-clonic
seizures, with an improved safety profile compared to
phenobarbital [10, 11]. Imepitoin currently has no spe-
cific add-on therapy label for combination treatment
with other AEDs. So far, only one pilot study [12] evalu-
ated the safety and efficacy of imepitoin administered
add-on to phenobarbital monotherapy. No severe ad-
verse drug reactions of the combination and a favorable
outcome comparable to add-on treatment with potas-
sium bromide were reported.
To obtain controlled information on the safety and
efficacy of combination treatment of imepitoin with
phenobarbital with or without other antiepileptic co-
medications in patients with drug resistance to previous
treatment, a single center, prospective, controlled, open
label, cohort study was initiated.
Methods
The study was conducted in 2013–2015 as a single cen-
ter, prospective, controlled, open label, cohort study in
client-owned dogs with drug resistant idiopathic epilepsy.
The study was conducted according to the ethical rules
of the University of Veterinary Medicine, Hannover,
Germany, with approval by the institutional animal
welfare officer, and with written informed consent of
the owners.
Study design
The study was designed to reflect the population of dogs
with drug-resistant epilepsy, as presenting in a veterinary
neurology referral center. In a first cohort (cohort A),
client owned dogs suffering from insufficient seizure
control from treatment with phenobarbital, with or with-
out co-medication with potassium bromide and/or leve-
tiracetam, were included. These patients were treated
add-on with imepitoin, using the labelled starting dose
of 10 mg/kg imepitoin, administered BID, with titration
steps allowed to 30 mg/kg BID. After collection of co-
hort A, two further cohorts were added. In cohort B, the
safety and efficacy of a lower starting add-on dose of
imepitoin of 5 mg/kg BID was evaluated, corresponding
to the protocol used previously evaluating the safety and
efficacy of imepitoin add-on to phenobarbital [12]. All
other in- and exclusion criteria were identical to cohort
A. This change was made due to observation of in-
creased seizure frequency or cluster seizures in four ani-
mals upon add-on administration of imepitoin in cohort
A. In addition, transient ataxia was observed in some of
the patients in cohort A following initiation of add-on
treatment with imepitoin. Cohort C was designed to
include patients not responding to imepitoin, with or
without add-on treatment with levetiracetam, to be
treated add-on with phenobarbital. For this cohort, a
low starting dose of 0.5 mg/kg BID phenobarbital was
selected to avoid described adverse drug reactions of
phenobarbital [3].
The diagnosis of idiopathic epilepsy was based on a
clinical and neurological examination as described by
Vandevelde et al. [13], and age of onset of epilepsy be-
tween 6 months and 6 years [2]. The diagnosis was veri-
fied using blood work, MRI, and CSF analysis (Tier II
confidence level for diagnosis of idiopathic epilepsy) [2].
For inclusion in cohort A or B, animals had to be treated
with phenobarbital for ≥ 8 weeks, or in case of potassium
bromide add-on treatment, for ≥ 3 months prior inclu-
sion, with proven therapeutic serum levels for phenobar-
bital (10–35 μg/ml) and potassium bromide (0.5-2.5 mg/
ml). Levetiracetam was allowed, either as baseline medi-
cation, or as pulse therapy at times of increased seizure
activity. For inclusion in cohort C, at least 6 weeks treat-
ment with imepitoin at the upper therapeutic dose range
(>20 mg/kg BID) was required. For all animals, at least
6 weeks seizure diary recordings were required, demon-
strating insufficient seizure control as defined by at least
1 generalized tonic-clonic seizure within 6 weeks prior
to inclusion despite serum levels of applied AEDs within
known therapeutic range [14], or treatment with imepi-
toin at a dose of >20 mg/kg BID (=baseline). Dogs with
cluster seizures as defined by more than one seizure
within less than 24 h [1] or status epilepticus as defined
by >5 min continuous epileptic seizure activity, or occur-
rence of two or more epileptic seizures with incomplete
recovery of consciousness between seizures [1] were
allowed to be included. Optional seizure diaries exceed-
ing the 6 weeks baseline period were recorded as seizure
history.
Dogs were specifically excluded for enrolment if their
case history included any of the following: Signs of se-
vere hepatic, renal or cardiac insufficiency, structural
epilepsy or reactive seizures, severe, unacceptable side
effects due to current/ongoing treatment, pregnancy or
lactation, administration of further AEDs, other than
phenobarbital, potassium bromide, levetiracetam or ime-
pitoin, or body weight below 5 kg.
After cohort assignment, add-on treatment was started
with 10 mg/kg or 5 mg/kg BID imepitoin (cohort A and
B) or 0.5 mg/kg BID phenobarbital (cohort C). Owners
were advised to generate a seizure diary, and to observe
the animals for potential adverse drug reactions. Follow-
ing inclusion, follow-up visits were scheduled after
4 weeks, 12 weeks, and 24 weeks. During each visit, the
seizure diary was reviewed and seizures as well as reported
suspected adverse drug reactions were transferred to the
study files. A general and neurological examination was
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conducted, and blood samples were taken for complete
blood cell count, biochemistry profile, and for phenobar-
bital and potassium bromide serum levels.
If seizure control was insufficient as observed upon
occurrence of seizure or cluster activity, the dose of the
add-on medication was increased, while the initial treat-
ment stayed unchanged. Scheduled visits, unscheduled
visits and phone contacts were utilized for dose adjust-
ments. Any dose adjustment was done as case-by-case
decision, taking into account the baseline seizure fre-
quency and seizure events occurring after initiation of
add-on treatment. In cohort A and B, dose adjustments
to up to 30 mg/kg BID in two to three steps were usually
done after at least one week of add-on treatment at the
previous dose level. In cohort C, the phenobarbital dose
was adjusted after at least two weeks of treatment at the
previous dose level, to allow steady state to be reached.
A top dose of 6 mg/kg BID was allowed, but not utilized
(Fig. 1). After the last study visit, owners were allowed
to continue add-on treatment, but were not followed
further. Premature termination was permitted, if seizure
reduction was still insufficient despite the dogs receiving
the maximum dose of the add-on treatment (imepitoin
30 mg/kg BID, phenobarbital 6 mg/kg BID), if phenobar-
bital serum levels were above 35 μg/ml, if severe side
effects occurred or if the owner elected euthanasia be-
cause of perceived lack of quality of life. Owners were
allowed to withdraw consent and to leave the study at
any time.
Statistical evaluation of efficacy and safety
Statistical evaluation was performed by independent per-
sons (CR, TK) to avoid a potential bias effect by clinical
investigators. All animals of each cohort which had re-
ceived at least one dose of add-on medication were in-
cluded in the primary evaluation of efficacy and safety.
Cohorts A and B as well as all three cohorts were also
pooled. In addition, the animals completing the full add-
on treatment period were evaluated separately.
The primary efficacy variable was the reduction in
monthly seizure frequency (MSF) during treatment com-
pared to the defined baseline period for the individual
dog. To calculate MSF, the seizures recorded during the
baseline period were counted. All documented generalized
Fig. 1 Study flow-chart
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tonic-clonic seizures, seizures during cluster, or status
events which had occurred during the 42 days of baseline
period were counted. Monthly seizure frequencies were
then calculated on the basis of one month notionally
equaling 28 days. For the add-on treatment period, the
same procedure was utilized, counting all seizure events
from first day of add-on treatment to study termination.
In addition, the monthly frequency of days with cluster
seizures (MCD) was calculated, counting all days with
more than one seizure event occurring on that day as clus-
ter day. This definition was selected instead of the defin-
ition of a cluster event as more than one seizure occurring
within less than 24 h, since for some seizure events ad-
equate time information was not available.
Because of the skewness of the distribution of seizure fre-
quency related measures, geometric means (GM) and 95%
confidence interval (CI) were calculated for MSF and MCD
for baseline and add-on treatment period. Because MCD
had some zero values, the smallest non-zero value of MCD
was added to each MCD value before log-transformation.
This offset was subtracted again from the antilog of the
mean and 95% and CI, to obtain the correct GM and 95%
CI. The percent decrease in MSF was calculated for each
dog individually as 100 x (1 – R) where R is the ratio of the
MSF during treatment to the MSF during baseline. To ob-
tain the estimated percent decrease + confidence interval
for each cohort and combined cohorts, in a first step the
GM and its 95% CI was calculated for R. The estimated
percent decrease in MSF between the baseline and treat-
ment periods and its CI were then obtained by applying the
expression 100x (1 – R) to the GM of R and to the upper
and lower CI endpoints, respectively, of the CI for R. To
calculate the percent decrease in MCD, the same procedure
was utilized, with the exception that the smallest observed
MCD interval had to be added to all baseline and treatment
results, to enable inclusion of animals which had had no
cluster days during the baseline period.
For MSF and MCD, the paired t-test was applied to
the corresponding log-transformed data values separ-
ately for each cohort and the combinations of cohorts
(i.e., cohort A + B and all 3 cohorts combined). P < 0.05
was considered significant, while p < 0.1 was accepted as stat-
istical trend. As confirmatory analysis, the data onMSF for co-
horts A to C were statistically evaluated via repeated-
measures analysis of variance of log-transformed values with
main effects for cohort and period and the interaction be-
tween cohort and period, followed by Fisher’s least-
significant-different comparisons per cohort of the mean dif-
ference between the baseline and treatment periods. Frequen-
cies of events were compared using Chi-square test.
Continuous baseline variables were compared using analysis
of variance with Bonferoni’smultiple comparison test.
The safety of the study treatments was assessed on the
basis of suspected adverse drug reactions (ADRs) re-
ported for all cases enrolled in the study (i.e., during
both the titration and evaluation of efficacy phases) fol-
lowing classification according to the VeDDRA list of
preferred terms of the system organ classes (European
Medicines Agency 2004; 2011). Laboratory data were
evaluated based on standard descriptive statistics and
were reviewed for conspicuous individual changes.
Results
In total 34 dogs were enrolled, with 16 dogs in cohort A,
11 dogs in cohort B, and 7 dogs in cohort C. All animals
met all of the inclusion criteria at screening, and none of
the dogs met an exclusion criterion. There was a pre-
dominance of male animals in all cohorts, with in total
26 males and 8 females. While less than 50% of males
were neutered, 7 out of 8 females were neutered. The
body weight of included animals was in the range of
7.3 kg - 58.4 kg, and there was no significant difference
in body weight distribution between cohorts. Nineteen
different breeds were enrolled, with Australian Shepherd,
Border Collie and Belgium Shepherd representing in
total 14 of 34 dogs. Because the study was a cohort
study, the animals were not randomized with regard to
their baseline characteristics. Instead, animals were se-
quentially included upon their appearance in the clinics.
As a result, animals differed somewhat in their demo-




























































1Chi-Square test comparing cohorts A, B and C
2Analysis of variance, with Bonferroni's multiple comparison test. *B > C, mean difference 2.2 years, confidence interval 0.34 to 4.06 years
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There was a trend that animals from cohort B appeared
to suffer from less severe disease as compared to cohort
A. Disease related differences were: the duration of epi-
lepsy prior to inclusion was shorter and the fraction of an-
imals which had suffered from status or cluster seizures
was lower in cohort B compared to cohort A. In fact, in
cohort A nearly all animals (87.5%) had suffered status or
cluster activity prior to inclusion, while in cohort B only
54.5% of dogs had suffered the same (Table 2). Cohort A
and B also differed in the baseline medication (Table 2).
The administered dose of phenobarbital was slightly lower
in cohort B compared to A, and the proportion of dogs
which were also treated with a 2nd baseline medication,
was 56.3% in cohort A and only 27.3% in cohort B.
Cohort C was again different, with much shorter dur-
ation of disease prior to inclusion and with no 2nd per-
manent baseline antiepileptic at inclusion. However, in
cohort C the rate of patients with cluster seizure activity
was comparable to cohort A, with 85.7% of animals hav-
ing experienced cluster seizures prior to inclusion.
Antiepileptic activity
Add-on treatment resulted in a mean reduction in MSF,
with some animals benefiting with more than 50% reduc-
tion in MSF, while others experienced an increase in MSF
(Fig. 2). While no animal became seizure free, two animals
in cohort A and one in cohort B experienced a reduction
by at least 75%. The mean reduction reached 15.46 and
39.41% for cohort A and C, while the reduction reached
35.73%, the difference being significant for cohort B (p =
0.043; Table 3). For cohort C, a trend towards reduction
(p = 0.063) was reached (Table 3). In cohort A, there was
one animal, which experienced a series of seizures and
cluster seizures following initiation of add-on treatment.
After 14 days, the participation of this animal in the study
was terminated and the add-on treatment with imepitoin
tapered. In this animal, a MSF of 32 was calculated for the
short treatment period which is more than 9 times the
mean MSF of the whole group during treatment. If this
animal was excluded from evaluation, the reduction in
MSF was within the same range as seen in the other co-
horts, i.e. 27.24% (Table 3, Fig. 3a). MSF reduction was
also calculated for the pooled cohort A and B, and for all
three cohorts. The MSF reduction for the full analysis set
gave a trend towards reduction (p = 0.06), while the
pooled cohort A + B failed to reach level of significance
(p = 0.18).
An increase in MSF of ≥50% was seen in fife (31.25%)
animals of cohort A and in only one animal (9.09%) in
cohort B. This increase was not seen in animals in
Table 2 Baseline characteristics
Parameter Dimension Cohort A Cohort B Cohort C Group comparison
Seizure activity related parameter









Mean ± SEM 950 ± 183 755 ± 180 512 ± 193


















Animals with cluster in baseline or history m/n (%) 14/16 (87.5%) 6/11 (54.5%) 6/7 (85.7%) p = 0.1133
Animals with status in baseline or history m/n (%) 4/16 (25%) 1/11 (9.1%) 2/7 (28.6%) p = 0.5093
Animals without cluster or status in
baseline or history
m/n (%) 2/16 (12.5%) 5/11 (45.5%) 1/7 (14.3%) p = 0.1133
Medication related parameter
Dose of phenobarbital (A, B) or imepitoin










Frequency of dogs with KBr at inclusion m/n (%) 7/16 (43.8%) 2/11 (18.2%) 0/7 (0%) p = 0.0693
p = 0.1664
Frequency of dogs with any 2nd
permanent antiepileptic at inclusion
m/n (%) 9/16 (56.3%) 3/11 (27.3%) 0/7 (0%) p = 0.0273
p = 0.1374
Frequency of dogs with levetiracetam
pulse therapy in baseline
m/n (%) 1/16 (6.3%) 4/11 (36.4%) 2/7 (28.6%) p = 0.1383
p = 0.0484
Add-on dose of imepitoin (A, B) or










1Analysis of variance, with Bonferroni's multiple comparison test
2t-Test comparing cohort A and B 3Chi-Square test comparing cohorts A, B and C 4Chi-Square test comparing cohort A and B
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cohort C (Fig. 2, 3b). All five animals of cohort A were
receiving potassium bromide (three dogs) or levetirace-
tam (two dogs) add-on. The animal in cohort B did also
receive potassium bromide.
As confirmatory analysis, the data on MSF for cohorts
A to C were statistically evaluated via repeated-measures
analysis of variance of log-transformed values with main
effects for cohort and period and the interaction
between cohort and period, followed by Fisher’s least-
significant-different comparisons per cohort of the mean
difference between the baseline and treatment periods.
The analysis revealed that the overall treatment effect
for the whole group (cohorts A, B and C combined) was
significant (p = 0.048), while the difference between the
three cohorts was not significant (p = 0.068). The treat-


























Fig. 2 Development of monthly seizure frequency during baseline (B) and add-on treatment (T). Individual animal values are displayed
Table 3 Decrease in monthly seizure frequency
95% Confidence Interval % of animals with
Variable Cohort N %Decrease LCL UCL p-value any reduction >50% reduction
MSF A 16 15.46 −67.03 57.22 0.607 50.0 37.5
A* 15* 27.24 −38.96 61.90 0.310 53.3 40.0
B 11 35.73 1.69 57.94 0.043 81.8 36.4
C 7 39.41 −3.77 64.58 0.063 71.4 42.9
A + B 27 26.29 −7.36 49.44 0.180 63.0 37.0
A + B + C 34 27.75 −1.51 48.57 0.060 64.7 38.2
MCD A 16 −16.77 −161.95 47.95 0.688
A* 15* 4.69 −98.58 54.25 0.890
B 11 17.88 −46.52 53.98 0.466
C 7 8.06 −105.03 58.77 0.806
A + B 27 −1.21 −68.03 −64.05 0.962
A + B + C 34 0.80 −50.53 34.69 0.969
MSF = (Number of Seizures/Number of days) x 28 days. MCD = (Number of Cluster days/Number of days) x 28 days. Significant %Decrease (p < 0.05) is bolded. In
addition, the paired t-test was applied to the corresponding log-transformed data values separately for each cohort and the two combinations of cohorts
(i.e., cohort A + B and all 3 cohorts combined). The displayed p-value is derived from this paired t-test. The fraction of animals showing any reduction and
>50% reduction of MSF (“Responder rate”) is given
*excluding animal No. 6 of cohort A as outlier
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the treatment cohorts individually. The lack of signifi-
cance for individual cohorts may be related to the low
number of animals per cohort.
The add-on treatment had little effect on cluster activ-
ity. Some animals had reduced, but others increased
MCD (Fig. 3b). In case of cohort A, there was a numer-
ical increase in MCD, but this was again driven primarily
by animal no. 6 (Table 3). Five animals of cohort A, two
of cohort B, and one of cohort C had no days with cluster
activity during the 6 weeks baseline, but during add-on
treatment. However, four of these animals had reported
cluster seizures in their seizure history, and two had sei-
zures on consecutive days during baseline, which fulfilled
the definition for a cluster seizure, but not MCD. For the
remaining two animals with new clusters, no seizure
history before the baseline period was available. Thus,
the initiation of add-on treatment was not associated
with occurrence of new clusters.
In addition to the full analysis set, the statistical ana-
lysis was repeated for the population of animals which
had completed the full treatment period of 24 weeks.
There were 5 completers in cohort A, 9 in cohort B, and
5 in cohort C (Table 4). There was no significant differ-
ence of baseline MSF and MCD between completer and
whole population (MSF completer 3.31 (CI: 2.3-4.75),
MSF whole population 3.84, (CI 2.95-4.98); MCD com-
pleter 0.72 (CI: 0.48-1.07; MCD whole population 0.65
(0.39-1.10)). Nevertheless, the treatment effect was more
pronounced in the completer population, reaching up to
73.4% (p = 0.072) reduction in MSF in cohort A, and
51.3% reduction overall (Table 4). The add-on treatment
effect reached level of significance for the whole completer
population (p = 0.002) and the combined completer cohort
A + B (p = 0.009), while for individual completer cohorts a
trend (p < 0.1) was observed. In the completer population,
a trend towards reduction of cluster activity was observed
for pooled cohort A and B (p = 0.055), while the cluster ac-
tivity was increased during the add-on treatment period in
cohort C (Table 4).
The study protocol was designed to allow a titration of
the add-on medication of imepitoin (cohort A and B),
and phenobarbital (cohort C), until a treatment effect
was reached, which was considered as adequate. In ani-
mals which completed the whole add-on treatment period,
the mean daily dose reached was 26.3 ± 3.4 mg/kg per day
in cohort A, and 29.3 ± 4.7 mg/kg per day for cohort B. In
contrast, the mean dose for the dogs which were termi-
nated early reached 48.3 ± 4.6 and 60.1 ± 3.1 mg/kg per
day in cohort A and B, respectively. This increased dose
may reflect the insufficient seizure control in the early ter-
minating sub-group, while it at the same time indicates,
that for add-on treatment a dose of about 15 mg/kg BID
was sufficiently active. In cohort C, the range of doses
reached varied widely from 1.2 to 6 mg/kg per day, with
no apparent difference between completers and early ter-






































































Fig. 3 Change in monthly seizure frequency (MSF, a) and in monthly cluster days (MCD, b) for each individual animal [%] and estimated
% reduction in MSF/MCD with 95% CI. Animals below the lower dotted line (>50% reduction) are responders, animals above the upper dotted
line had >50% increase in MSF or MCD. Dogs between the dotted lines (−50% to +50%) had no clinically meaningful change of MSF or MCD.
Note, that 8 animals had only clusters during add-on treatment, but not during baseline (open symbols). Four of those had reported clusters in
their seizure history, two had seizures on sequential days during baseline, and for two, no seizure history was available
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treatment, the serum levels of phenobarbital and potas-
sium bromide (where applicable) were determined. In co-
hort A and B, plasma levels of phenobarbital were mostly
within the therapeutic range of 10–35 μg/ml, however in
few animals the therapeutic range was exceeded. All ani-
mals receiving potassium bromide had plasma levels
within the therapeutic range of 0.5 to 2.5 mg/ml. At the
end of the add-on treatment period, phenobarbital levels
had reached the therapeutic range in cohort C (data not
shown). Add on treatment with imepitoin did not signifi-
cantly change plasma levels of phenobarbital and potas-
sium bromide in cohort A and B.
Safety
Adverse drug reactions were observed during baseline
treatment (retrospective reporting) and during the add-
on period. Due to high dose baseline treatment with
phenobarbital, in part with add-on potassium bromide
or levetiracetam, many ADRs were reported during
baseline. In cohort A and B, ataxia and polyphagia were
the most frequent ADR during baseline (5 of 27 dogs
each), followed by reduced activity (4 of 27). Ataxia was
not reported in cohort C during baseline, while polypha-
gia and reduced activity was reported at a similar rate.
Aggressive behavior and restlessness was observed in co-
hort A and B (3 of 27 dogs), while no aggression, but
some restlessness was seen in cohort C. Other ADRs were
observed in individual animals only. Following initiation
of add-on treatment, the number of ADRs reported
increased. Ataxia was the single most frequent ADR,
followed by reduced activity. Upon continuation of add-on
treatment, the number of ADRs fell again to reach the
pre-add-on values. In line with the highest treatment in-
tensity in cohort A, the rate of ADRs was highest in this
cohort. There was one additional observation made: in
some patients treated add-on with imepitoin, owners re-
ported that animals became more lively as compared to
the baseline period. While this is likely a drug-induced
finding, it was not categorized as ADR.
Five animals were euthanized on owner’s request dur-
ing the course of the study, i.e. prior to conclusion of
the 24 weeks add-on treatment period. All 5 patients
were from cohort A. The primary reason for euthanasia
was lack of efficacy/reduced quality of life. While it is
notable that all euthanized animals were from cohort A,
this correlated with the observed increased baseline se-
verity of epilepsy and increased treatment intensity in
this cohort.
Table 4 Decrease in monthly seizure frequency, completer population
95% Confidence Interval % of animals with
Variable Cohort N %Decrease LCL UCL p-value any reduction >50% reduction
MSF A 5 73.42 −20.92 94.16 0.072 80.0 80.0
B 9 37.12 −2.43 61.36 0.059 88.9 33.3
C 5 43.56 −14.11 72.06 0.087 80.0 40.0
A + B 14 53.74 20.31 73.15 0.009 85.7 50.0
A + B + C 19 51.28 26.58 67.63 0.002 84.2 47.4
MCD A 5 59.75 −78.25 90.92 0.165
B 9 25.55 −27.00 56.35 0.239
C 5 −20.92 −262.19 59.67 0.656
A + B 14 40.25 −1.21 64.73 0.055
A + B + C 19 28.04 −12.98 54.21 0.143
MSF = (Number of Seizures/Number of days) x 28 days. MCD = (Number of Cluster days/Number of days) x 28 days. Significant %Decrease (p < 0.05) is bolded. In
addition, the paired t-test was applied to the corresponding log-transformed data values separately for each cohort and the two combinations of cohorts
(i.e., cohort A + B and all 3 cohorts combined). The displayed p-value is derived from this paired t-test. The fraction of animals showing any reduction and






























































Fig. 4 Dose of imepitoin (cohort A and B) and phenobarbital
(cohort C) at study termination, separately displayed for animals
which completed the full add-on treatment phase of 24 weeks (filled
symbols, completer), and animals which terminated early the add-on
treatment for various reasons (open symbols, termination). For each
sub-cohort, in addition mean ± SEM is given
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The add-on treatment was without effect on haemato-
logical parameters. At baseline, the majority of animals
undergoing phenobarbital treatment in cohorts A and B
had liver enzyme levels within the normal range, but a
fraction of animals had in part strongly elevated liver en-
zymes, alkaline phosphatase being the most sensitive
parameter. Upon initiation of add-on treatment with
imepitoin, there was no change in liver enzyme levels. In
animals undergoing imepitoin treatment at baseline, all
animals were within the normal range for all liver en-
zymes. Upon initiation of low dose phenobarbital treat-
ment, there was no change in liver enzyme levels. For
both urea and creatinine, there were no clinical relevant
deviations from normal range throughout the study.
Discussion
In approximately 20-40% of the dogs with idiopathic
epilepsy under treatment, seizure reduction may not be
adequate using only one AED [3]. One strategy to over-
come drug resistance is to combine two or more antiepi-
leptic treatments. Imepitoin is currently not approved for
combination treatment with other AEDs. So far, only one
study [12, 15] evaluated the safety and efficacy of imepi-
toin administered add-on to phenobarbital, and compared
the results with add-on treatment with potassium brom-
ide. In this study, only patients with monotherapy of
phenobarbital were included. The effect of imepitoin add-
on to phenobarbital was similar to the effect of potassium
bromide, but the study population was small [12, 15].
The aim of the current study was to get further
insight into the safety and efficacy of a combination of
phenobarbital with imepitoin. To best reflect the clin-
ical situation, patients receiving more than one baseline
medication were allowed to be included in this study.
Thus, patients with phenobarbital with or without add-
on potassium bromide or levetiracetam were included.
The diagnosis of idiopathic epilepsy was verified using
not only clinical criteria and blood work, but also MRI
and of CSF analysis, to exclude structural epilepsy or
reactive seizures, in accordance with the current rec-
ommendations (tier II confidence level) [2]. The study
was designed as open-label monocentric cohort study.
No separate control group was included. While the lack
of a comparator control group prevented the statistical
evaluation of placebo effects and fluctuations of seizure
activity over time, an attempt to compensate for this
deficit was made through use of a defined baseline period
of 6 weeks, with diligent seizure recordings using a seiz-
ure diary, to form the basis for an individual patient
pre-post comparison.
The three cohorts included in the study were not dif-
ferent with regard to gender, breed, or body weight. Sev-
eral breeds and mixed breeds were included. Australian
Shepherds and Border Collies, both known for epilepsy
predisposition with severe seizures [4, 5], were most fre-
quently represented, contributing together about one
third of the patients. However, the three cohorts tended
to differ in their baseline characteristics. Animals in-
cluded in cohort A had a tendency to suffer from more
severe epilepsy as compared to cohort B and C, as
reflected by a longer duration of epilepsy, highest MSF,
rate of animals with cluster seizure activity and status
epilepticus, dose of phenobarbital, rate of animals with
potassium bromide or permanent levetiracetam in base-
line, and rate of reported ADRs during baseline. The in-
dividual differences however did not reach level of
significance. Animals in cohort C had the shortest dur-
ation of epilepsy, but had a high rate of cluster activity
during baseline. The reason for this difference is not en-
tirely clear. One possible explanation is that initially,
when cohort A was started, cases of drug-resistant patients
which had unsuccessfully explored add-on treatment with
potassium bromide or levetiracetam were included, while
upon start of cohort B and C, most patients included had
failed only their first antiepileptic therapy. For those, the
treating veterinarian could choose to participate in the
study or try potassium bromide or levetiracetam. Indeed,
in cohort A 56.3% of animals had a 2nd permanent antiepi-
leptic medication during baseline, while only 27.3% of pa-
tients in cohort B had this 2nd AED in baseline. These
differences in baseline medication and underlying disease
characteristics need to be taken into consideration if
cohorts are compared. Bromides are known for their
narrow margin of safety [16]. The most common adverse
effects seen with potassium bromide with or without
phenobarbital combination treatment are polydipsia, poly-
phagia, and increased lethargy [16]. The high frequency of
dogs treated with potassium bromide in cohort A may be
the reason why the rate of adverse drug reactions is high-
est in cohort A during baseline. The rate of dogs with
cluster seizures during baseline was higher in cohort A
compared to cohort B. The tendency to develop cluster
seizures or status epilepticus has been found to negatively
influence the treatment outcome in dogs with epilepsy
[17, 18]. Thus, animals in cohort A can be expected to be
more treatment resistant as compared to cohort B.
Treatment of imepitoin add-on to phenobarbital re-
sulted in a reduction of the MSF by about one third.
The reduction of MSF was enlarged, if only the com-
pleter population of the pooled cohorts A and B was
evaluated. This effect is identical in frequency and effect
size to the effect of potassium bromide added to pheno-
barbital in a previous study [19]. The authors report for
those animals followed for 1 year after initiation of po-
tassium bromide therapy a reduction in seizure fre-
quency in 83% of dogs, and on average, a 53% reduction
in the number of seizures compared with the previous
12 months.
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The add-on treatment had no clinically relevant effect
on cluster activity. Neither the frequency of cluster sei-
zures, nor the fraction of animals suffering from cluster
seizures was changed following initiation of add-on
treatment with imepitoin or phenobarbital. The initiation
of add-on treatment was not associated with occurrence
of new clusters. Neither treatment of imepitoin add-on to
phenobarbital with or without potassium bromide or leve-
tiracetam, nor treatment of phenobarbital add-on to ime-
pitoin with or without levetiracetam had a significant
influence on MCD. In fact, cluster seizures and younger
age at onset haven been identified as predictors for treat-
ment resistance [5, 17, 18, 20]. However, individual ani-
mals benefited from the add-on treatment, with more
than 50% reduction in cluster activity (Fig. 3B).
Aggravation of seizure activity was primarily seen in
cohort A, with only one case in cohort B. The under-
lying cause for this aggravation is not known. All five an-
imals experiencing ≥50% increase in MSF were receiving
potassium bromide (three dogs) or levetiracetam (two
dog) add-on. In patients receiving potassium bromide,
three drugs (phenobarbital, imepitoin, KBr) are adminis-
tered which all act at the GABAergic synapse. While it is
well understood, that benzodiazepines and barbiturates
are acting synergistically on the GABAergic synapse
[21], little is known about how potassium bromide, in
part replacing the chloride influx, interacts as a 3rd
modulator. Since three other animals with potassium
bromide add-on in baseline and one animal with leveti-
racetam add-on in baseline were experiencing a ≥50%
reduction in MSF, one can conclude, that potassium
bromide is not per se a predictor of seizure aggravation.
Changes in seizure frequency are a common feature of the
disease. Even in the study evaluating potassium bromide
add-on to phenobarbital, only 83% of dogs had nominally
reduced MSF, leaving 17% of animals with seizure aggrava-
tion [19]. In cohort B, using a low starting dose of imepi-
toin, only one out of 11 dogs showed a >50% increase in
MSF. This indicates that combination of phenobarbital
and imepitoin is well possible. Seizure aggravation was
limited to only a few cases when using a low starting dose
of imepitoin, but this finding should be explored in a
larger cohort.
The pharmacological effect of imepitoin was also
evaluated separately in the completer population. These
patients represent a population where the owners were
willing to continue the add-on treatment, indicating
that the combination may have had a positive effect on
quality of life of their dogs, albeit this was not evalu-
ated. In this population, a dose of about 15 mg/kg BID
imepitoin was administered, resulting in a significant
mean reduction of 53.7%, with 85.7% of dogs showing a
nominal reduction in MSF. The dose escalation was
not limited by safety issues, since in animals with
insufficient seizure control the dose was safely raised to
up to 30 mg/kg BID. The titration results underscore
that imepitoin is a potent anticonvulsant in responder
animals, while other animals remain treatment resistant
even with the highest dose applied.
The phenobarbital add-on dose was found to be in the
lower therapeutic range of 3.2 ± 0.84 mg/kg per day in
cohort C (about 1.6 mg/kg BID), which is less than half
the dose of phenobarbital administered in cohort A and
B as baseline medication. This low dose of phenobarbital
was sufficient to reduce the MSF in 5 out of 7 evaluated
dogs. The use of phenobarbital add-on to imepitoin may
thus allow a lower dose of phenobarbital and may result
in a long-term safety advantage, compared to high-dose
phenobarbital monotherapy. However, the results in co-
hort C indicate, that low dose phenobarbital treatment
add-on to imepitoin was not capable of reducing the
cluster seizure activity in imepitoin-resistant dogs.
Conclusion
The data indicate that combination treatment of imepi-
toin and phenobarbital is well tolerated in dogs with
drug-resistant epilepsy. The efficacy results must be
interpreted cautiously in view of the lack of adequate
placebo control and randomization. While not all ani-
mals benefit from the combination treatment, a clinically
meaningful reduction in seizure frequency of ≥50% was
obtained in 36-42% of all animals. The effect size in ani-
mals completing the study was comparable to the effect
size of potassium bromide reported by others, but potas-
sium bromide is less well tolerated than imepitoin. The
lower starting dose of 5 mg/kg BID imepitoin was found
to be better tolerated than the higher starting dose of
10 mg/kg BID, and an up-titration to on average 15 mg/kg
BID was sufficient. Neither imepitoin nor phenobarbital
add-on treatment was capable of suppressing cluster seiz-
ure activity, making cluster seizure activity an important
predictor for drug-resistance.
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